This inventor holds 1 USPTO granted patent. Top assignee: Nanjing Anji Biological Technology Co., Ltd. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Erhao Zhang - Innovator in Cellular Immunotherapy
Introduction
Erhao Zhang is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of cellular immunotherapy, particularly in the development of innovative therapeutic techniques for tumor treatment. His work focuses on enhancing the efficacy and safety of CAR-T cell therapies.
Latest Patents
Erhao Zhang holds a patent for a "Dual chimeric antigen receptor-t cell which can be regulated, construction method therefor and use thereof." This invention introduces a novel switchable dual chimeric antigen receptor-T (sdCAR-T) cell, which is designed to improve the application of CAR-T cell immunotherapy. The dual chimeric antigen receptor consists of a first receptor targeting MSLN and a second receptor targeting FITC. The invention allows for the construction of dual-targeted functional T cells that can be regulated by specific exogenous bifunctional molecules. Through in vitro and in vivo tests, it has been confirmed that the activation of the constructed CAR-T cell is controlled by the combination of endogenous tumor antigens and exogenous bifunctional molecules. This innovative approach significantly enhances the safe application of CAR-T cell immunotherapy.
Career Highlights
Erhao Zhang is associated with Nanjing Anji Biological Technology Co., Ltd., where he continues to advance his research in cellular immunotherapy. His work has garnered attention for its potential to revolutionize cancer treatment through improved immunotherapeutic strategies.
Collaborations
Erhao Zhang collaborates with Hanmei Xu, contributing to the development of innovative solutions in the field of immunotherapy. Their partnership aims to enhance the effectiveness of cancer treatments through advanced research and development.
Conclusion
Erhao Zhang's contributions to cellular immunotherapy exemplify the potential of innovative approaches in cancer treatment. His patented work on dual chimeric antigen receptor-T cells represents a significant advancement in the field, promising improved safety and efficacy in immunotherapy applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile